Skip to main content
INDP
NASDAQ Life Sciences

Director Disposes of Preferred Stock Convertible to 108.9M Common Shares Amidst Going Concern Warning

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
8
Price
$1.7
Mkt Cap
$3.812M
52W Low
$1.52
52W High
$21.84
Market data snapshot near publication time

summarizeSummary

A director of Indaptus Therapeutics disposed of preferred stock convertible into 108.9 million common shares, following the company's recent going concern warning and massive dilution.


check_boxKey Events

  • Director Disposes of Significant Preferred Stock Holdings

    Director David E. Lazar disposed of 896,800 shares of Series AA and Series AAA Convertible Non-Redeemable Preferred Stock on March 23, 2026. These preferred shares were convertible into an aggregate of 108,936,000 shares of common stock.

  • Transaction Reported with $0 Value

    The disposition of these derivative securities was reported with a transaction value of $0, as per the filing details for the preferred stock itself.

  • Context of Company Distress

    This disposition follows closely on the heels of the company's 10-K filing on March 17, 2026, which included a going concern warning, halted its lead clinical program, and announced a 'rescue' financing resulting in over 98% dilution for existing shareholders.

  • Remaining Holdings

    Following the transaction, the reporting person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.


auto_awesomeAnalysis

Director David E. Lazar's disposition of preferred stock convertible into a massive 108.9 million common shares is a highly significant event, especially given Indaptus Therapeutics' recent disclosure of a going concern warning and a highly dilutive financing. While the reported transaction value for the derivative itself is $0, the sheer volume of underlying common shares involved represents a substantial shift in potential ownership and control. This action by a director, following such dire financial news, sends a strong negative signal regarding insider confidence and the company's future prospects. Investors should view this as a further indication of the severe challenges facing the company.

At the time of this filing, INDP was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $1.52 to $21.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed INDP - Latest Insights

INDP
Apr 03, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
8
INDP
Mar 30, 2026, 9:46 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
INDP
Mar 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
10
INDP
Mar 24, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
INDP
Mar 24, 2026, 4:02 PM EDT
Filing Type: 4
Importance Score:
8